The promise of immuno-oncology has attracted many players to the space. More than 130 biotechs and 20 pharmaceutical companies are working on immuno-oncology therapies, according to a new report from the Tufts Center for the Study of Drug Development. Read More
Bannockburn, Ill.-based Baxalta Inc. is helping set the pace toward another active year for partnership and licensing transactions. Late last month the company completed its second deal, reporting it was hooking up with Precision Bioscience Inc. in a potential $1.7 billion, six-target cancer deal centered on its gene editing technology. Baxalta paid $105 million up front with the rest earmarked for milestone payments. Read More